A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Dezapelisib (Primary) ; Itacitinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 08 May 2017 Status changed from completed to discontinued.
- 18 Jan 2017 Status changed from active, no longer recruiting to completed.
- 13 Jan 2016 Status changed from not yet recruiting to active, no longer recruiting as per ClinicalTrials.gov record.